DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin

Toxicological Sciences

Volumn 85, Issue 2, 2005, Pages 870-879

  Montaner, Beatriz ^a   Castillo Ávila, Wilmar ^a   Martinell, Marc ^a   Öllinger, Rupert ^a   Aymami, Joan ^b   Giralt, Ernest ^a   Pérez Tomás, Ricardo ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

Author keywords

DNA damage; Prodigiosin; Topoisomerase inhibition

Indexed keywords

ADENINE; ALKALOID; APOPTOSIS INDUCING FACTOR; COPPER; CYTOSINE; DNA; DNA BASE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GUANINE; PRODIGIOSIN; PYRROLE; THYMINE;

APOPTOSIS; ARTICLE; ASSAY; CANCER CELL CULTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA BINDING; DNA CLEAVAGE; DNA DAMAGE; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; INTERCALATION COMPLEX; PH; PULSED FIELD GEL ELECTROPHORESIS; SERRATIA MARCESCENS;

ANTIBIOTICS, ANTINEOPLASTIC; BINDING, COMPETITIVE; BLOTTING, SOUTHERN; CELL LINE, TUMOR; CELLS, CULTURED; COPPER; DIALYSIS; DNA; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOHISTOCHEMISTRY; INTERCALATING AGENTS; JURKAT CELLS; PLASMIDS; PRODIGIOSIN;

SERRATIA MARCESCENS;

EID: 20544435208     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/kfi149     Document Type: Article

References (41)

1. Baguley, B. C., Wakelin, L. P., Jacintho, J. D., and Kovacic, P. (2003). Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress? Curr. Med. Chem. 10, 2643-2649.
2. Bible, K. C., Bible, R. H., Kottke, Jr. T. J., Svingen, P. A., Xu, K., Pang, Y. P., Hadju, E., and Kaufmann, S. H. (2000). Flavopiridol binds to duplex DNA. Cancer Res. 60, 2419-2428.
3. Boger, D. L., and Patel, M. (1988). Total synthesis of prodigiosin, prodigiosene, and desmethoxyprodigiosin: Diels-Alder reactions of heterocyclic azadienes and development of an effective palladium (II)-promoted 2,2′-bipyrrole coupling procedure. J. Org. Chem. 53, 1405-1415.
4. Borah, S., Melvin, M. S., Lindquist, N., and Manderville, R. A. (1998). Copper-mediated nuclease activity of a tambjamine alkaloid. J. Am. Chem. Soc. 120, 4557-4562.
5. Boyd, M. R. (1987). The NCI in vitro anticancer drug discovery screen: concept, implementation, and operation, 1985-1995. In Anticancer drug development guide: preclinical screening, clinical trials, and approval (B. A. Teicher, Ed.), pp. 23-42. Humana Press, Totowa, NY.
6. Branum, M. E., and Que, L., Jr. (1999). Double-strand DNA hydrolysis by dilenthandine complexes. J. Biol. Inorg. Chem. 4, 593-600.
7. Cameron, R., and Feuer, G. (2000). Molecular, cellular and tissue reactions of apoptosis and their modulation by drugs. In Handbook of experimental pharmacology (R. D. Cameron, and L. A. Feuer, Eds.), pp. 37-58. Springer, Berlin.
8. Campas, C., Dalmau, M., Montaner, B., Barragan, M., Bellosillo, B., Colomer, D., Pons, G., Perez-Tomas, R., and Gil, J. (2003). Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia. Leukemia 17, 746-750.
9. D'Alessio, R., Bargiotti, A., Carlini, O., Colotta, F., Ferrari, M., Gnocchi, P., Isseta, A., Mongelli, N., Motta, P., Rossi, A., et al. (2000). Synthesis and immunosuppressive activity of novel prodigiosin derivatives. J. Med. Chem. 43, 2557-2565.
10. Froelich-Ammon, S.J., and Osheroff, N. (1995). Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270, 21429-21432.
11. 31P-MRS measurements of extracellular pH tumors using 3-aminopropylphosphonate. Am. J. Physiol. 267, 195-203.
12. Holden, J. A. (2001). DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic. Curr. Med. Chem. Anticancer Agents 1, 1-25.
13. Hurley, L. H. (2002). DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer 3, 188-200.
14. Kaufmann, S. H. (1998). Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim. Biophys. Acta 1400, 195-211.
15. Khanna, K. K., and Jackson, S. P. (2001). DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 2, 247-254.
16. Kozin, S., Shkarin, P., and Gerweck, L. (2001). The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res. 61, 4740-4743.
17. Lisgarten, J., Coll, M., Portugal, J., Wright, C. W., and Aymami, J. (2002). The antimalarial drug cryptolepine intercalates specifically into DNA at cytosine-cytosine sites. Nature Struct. Biol. 9, 57-60.
18. Melvin, M. S., Ferguson, D. C., Lindquist, N., and Manderville, R. A. (1999). DNA binding by 4-methoxypyrrolic natural products. Preference for intercalation at AT sites by tambjamine E and prodigiosin. J. Org. Chem. 64, 6861-6869.
19. Melvin, M. S., Tomlinson, J. T., Saluta, G. R., Kucera, G.L., Lindquist, N., and Manderville, R. A. (2000). Double-strand DNA cleavage by copper prodigiosin. J. Am. Chem. Soc. 122, 6333-6334.
20. Montaner, B., Navarro, S., Pique, M., Vilaseca, M., Martinell, M., Giralt, E., Gil, J., and Perez-Tomas. R. (2000). Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines. Br. J. Pharmacol. 131, 585-593.
21. Montaner, B., and Perez-Tomas, R. (2001). Prodigiosin-induced apoptosis in human colon cancer cells. Life Sci. 68, 2025-2036.
22. Montaner, B., and Perez-Tomas, R. (2002a). Activation of protein kinase C for protection of cells against apoptosis induced by the immunosuppressor prodigiosin. Biochem. Pharmacol. 63, 463-469.
23. Montaner, B., and Perez-Tomas, R. (2002b). The cytotoxic prodigiosin induces phosphorylation of p38-MAPK but not of SAPK/JNK. Toxicol. Lett. 129, 93-98.
24. Perez-Tomas, R., and Montaner, B. (2003). Effects of the proapoptotic drug prodigiosin on cell cycle-related proteins in Jurkat T cells. Histol. Histopathol. 18, 379-385.
25. Perez-Tomas, R., Montaner, B., Llagostera, E., and Soto-Cerrato, V. (2003). The prodigiosins, proapoptotic drugs with anticancer properties. Biochem. Pharmacol. 66, 1447-1452.
26. Pons, M., Campayo, L., Martinez-Balbas, M. A., Azorin, F., Navarro, P., and Giralt, E. (1991). A novel ionisable chromophore of 1,4-bis (alkylamino)-benzo[g]phthalazine which interacts with DNA by intercalation. J. Med. Chem. 34, 82-86.
27. Poo, J. L., Romero, R. R., Robles, J. A., Momtemayor, A. C., Isoard, F., Estanes, A., and Uribe, M. (1997). Diagnostic value of the copper/zinc ratio in digestive cancer: a case control study. Arch. Med. Res. 28, 259-263.
28. Portugal, J., Martin, B., Vaquero, A., Fencer, N., Villamarin, S., and Priebe, W. (2001). Analysis of the effects of daunorubicin and WP631 on transcription. Curr. Med. Chem. 8, 1-8.
29. Ren, J., and Chaires, J. B. (1999). Sequence and structural selectivity of nucleic acid binding ligands. Biochemistry 38, 16067-16075.
30. Rogakou, E. P., Boon, C., Redon, C., and Bonner, W. M. (1999). Megabase chromatin domains involved in DNA double-strand breaks in vivo. J. Cell. Biol.146, 905-916.
31. Rogakou, E. P., Nieves-Neira, W., Boon, C., Pommier, Y., and Bonner, W. M. (2000). Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX historic at serine 139. J. Biol. Chem. 275, 9390-9395.
32. Songia, S., Mortellaro, A., Taverna, S., Fornasiero, C., Scheiber, E. A., Erba, E., Colotta, F., Mantovani, A., Isetta, A. M., and Golay, J. (1997). Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes. J. Immunol. 158, 3987-3995.
33. Soto-Cerrato, V., Llagostera, E., Montaner, B., Scheffer, G. L., and Perez-Tomas, R. (2004). The novel anticancer agent prodigiosin triggers mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells. Biochem. Pharmacol. 68, 1345-1352.
34. Susin, S. A., Daugas, E., Ravagnan, L., Samejima, K., Zamzami, N., Loeffler, M., Costantini, P., Ferri, K. F., Irinopoulou, T., Prevost, M. C., et al. (2000). Two distinct pathways leading to nuclear apoptosis. J. Exp. Med. 192, 571-579.
35. Theophanides, T., and Anastassopoulou, J. (2002). Copper and carcinogenesis. Crit. Rev. Oncol. Hemat. 42, 57-64.
36. Turner, P. R. and Denny, W. A. (1996). The mutagenic properties of DNA minor-grove binding ligands. Mutat. Res. 355, 141-169.
37. Vukovic, V., and Tannock, I. F. (1997). Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br. J. Cancer 75, 1167-1172.
38. Wike-Hooley, J. L., Haveman, J., and Reinhold, J. S. (1984). The relevance of tumor pH to the treatment of malignant disease. Radiother. Oncol. 2, 343-366.
39. - symporter, induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografts in nude mice. Hepatology 30, 894-902.
40. - symporter, induces apoptosis in human breast cancer cell lines. J. Cancer Res. Clin. Oncol. 126, 191-197.
41. - symporter, induces apoptosis and differentiation in HL-60 cells. Int. J. Cancer 88, 121-128.